INCY Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Company profile
Ticker
INCY
Exchange
Website
CEO
Herve Hoppenot
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
943136539
INCY stock data
()
News
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
8 Apr 21
Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal
8 Apr 21
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
7 Apr 21
Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $86
5 Apr 21
Incyte's Pemazyre Wins European Approval For Bile Duct Cancer
29 Mar 21
Press releases
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
8 Apr 21
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
6 Apr 21
Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
29 Mar 21
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
23 Mar 21
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
18 Mar 21
Calendar
9 Feb 21
11 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Incyte earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.51B | 1.51B | 1.51B | 1.51B | 1.51B | 1.51B |
Cash burn (monthly) | (positive/no burn) | 26.58M | (positive/no burn) | 21.97M | (positive/no burn) | 10.38M |
Cash used (since last report) | n/a | 90.17M | n/a | 74.55M | n/a | 35.23M |
Cash remaining | n/a | 1.42B | n/a | 1.44B | n/a | 1.48B |
Runway (months of cash) | n/a | 53.6 | n/a | 65.5 | n/a | 142.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 21 | Dhanak Dashyant | Common Stock | Sell | Dispose S | No | Yes | 81.57 | 396 | 32.3K | 27,336 |
31 Mar 21 | Baker Bros. Advisors | Common Stock | Grant | Aquire A | Yes | No | 0 | 364 | 0 | 29,314,516 |
31 Mar 21 | Baker Bros. Advisors | Common Stock | Grant | Aquire A | Yes | No | 0 | 364 | 0 | 2,850,749 |
31 Mar 21 | Clancy Paul J | Common Stock | Grant | Aquire A | No | Yes | 81.27 | 298 | 24.22K | 5,094 |
31 Mar 21 | Dixon Wendy L | Common Stock | Grant | Aquire A | No | Yes | 81.27 | 225 | 18.29K | 14,878 |
31 Mar 21 | Harrigan Edmund | Common Stock | Grant | Aquire A | No | Yes | 81.27 | 219 | 17.8K | 2,711 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
92.1% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 486 |
Opened positions | 67 |
Closed positions | 65 |
Increased positions | 177 |
Reduced positions | 164 |
13F shares |
Current |
---|---|
Total value | 19.83B |
Total shares | 202.54M |
Total puts | 731.8K |
Total calls | 598.3K |
Total put/call ratio | 1.2 |
Largest owners |
Shares | Value |
---|---|---|
TROW T. Rowe Price | 32.59M | $2.84B |
Baker Bros. Advisors | 32M | $2.78B |
Vanguard | 20.16M | $1.75B |
BLK Blackrock | 17.81M | $1.55B |
Wellington Management | 13.5M | $1.17B |
STT State Street | 8.69M | $755.78M |
Capital International Investors | 6.79M | $590.58M |
Renaissance Technologies | 5.89M | $512.24M |
Geode Capital Management | 3.25M | $282.39M |
Dodge & Cox | 3.25M | $282.91M |
Financial report summary
?Competition
Geron • CTI BioPharma • Exelixis • Curis • Infinity Pharmaceuticals • Lumos Pharma • Sierra Oncology • AVEO Pharmaceuticals • AnaptysBio • SELLAS Life SciencesContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adaptive, AEs, aggressive, aid, AIHA, Allergy, ancestry, appetite, arm, ascertain, ASCT, ASH, baccalaureate, BAT, benchmarking, bendamustine, binary, BIRC, Black, Blinded, BOR, BRAVE, broaden, Brown, budgetary, Canada, Canadian, canal, carefully, caution, CCA, CCPA, Cohort, color, compliant, compromise, confidence, constrain, constrained, context, conventional, cracked, creative, creed, culture, Defense, developmental, dialogue, dictated, discriminate, dMMR, DOR, economy, EHS, emerge, emergency, England, enrichment, enterprise, epidemic, equitably, ESMO, Estate, EUA, excellence, ExpirationIncluding, extracorporeal, fashion, febrile, firstMIND, FOP, freely, frontMIND, gender, geography, goal, graduate, Hall, harassment, home, HS, hybrid, IAI, Ib, ill, impede, inclusion, inclusive, infection, inMIND, Internet, invasive, job, Jopwell, Journal, Katherine, Labour, lenalidomide, lifeblood, lymph, marital, MCC, mDOR, median, membrane, mental, mentoring, microsatellite, military, mismatch, MONJUVI, Montreal, mortality, Motion, movement, myeloma, na, nausea, negligible, NIAID, Nimble, nonrefundable, North, numerical, orientation, outbreak, outset, outsourced, oxygen, oxygenation, pandemic, participatory, partnership, pathogenic, payroll, pemazyre, peptide, petitioner, philosophy, plamotamab, pneumonia, PoC, Pocket, post, prioritization, prioritize, proactive, prolonged, pronounced, proud, PRV, PTE, QD, quarantine, question, race, RAD, radio, RECIST, recurrent, reimposition, remdesivir, remote, remotely, reopened, reopening, repair, respiratory, resurgence, retaliation, retifanlimab, Revolutionizing, rituximab, Rodino, RUXCOVID, SCAC, sex, sexual, Shield, shutdown, slower, SMDP, SoC, Society, sought, SPC, standalone, stay, storm, strain, strong, suboptimal, suspected, sweat, sweeping, swollen, symposium, TABRECTA, television, Town, Treasury, trillion, TrOOP, Trump, tuition, uncollectible, underrepresented, underwritten, unpredictable, unusual, utmost, ventilation, veteran, virtual, voluntarily, vomiting, voucher, widespread, worth, Wuhan, XmAb
Removed:
acceleration, actuarial, adjusted, affiliated, annum, assured, AtD, Bank, block, Brooke, concept, customary, deducting, deduction, derivative, discontinued, Extensionsand, flare, Israel, mature, minimum, moderate, Norway, partially, persuasive, PIM, placement, possession, proof, redeem, refund, refundable, released, rendered, RESET, Russia, satisfying, scaly, Securing, subside, tackle, transition, trustee, Turkey, Unionand, visit
Financial reports
10-K
2020 FY
Annual report
9 Feb 21
10-Q
2020 Q2
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
13 Feb 20
10-Q
2019 Q3
Quarterly report
29 Oct 19
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
30 Apr 19
10-K
2018 FY
Annual report
13 Feb 19
10-Q
2018 Q3
Quarterly report
30 Oct 18
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
19 Feb 21
8-K
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs
9 Feb 21
8-K
Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
5 Nov 20
8-K
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
4 Aug 20
8-K
Departure of Directors or Certain Officers
27 May 20
8-K
Departure of Directors or Certain Officers
14 May 20
8-K
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
5 May 20
8-K
Departure of Directors or Certain Officers
20 Apr 20
8-K
Departure of Directors or Certain Officers
26 Mar 20
8-K
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
13 Feb 20
Registration and prospectus
S-8
Registration of securities for employees
15 Jun 20
S-8
Registration of securities for employees
30 Apr 19
S-3ASR
Automatic shelf registration
14 Feb 19
S-8
Registration of securities for employees
24 May 18
424B2
Prospectus for primary offering
10 Sep 17
424B3
Prospectus supplement
7 Sep 17
424B7
Prospectus with selling stockholder info
9 Mar 17
S-8
Registration of securities for employees
16 Jun 16
S-8
Registration of securities for employees
16 Jun 16
S-3ASR
Automatic shelf registration
23 Feb 16
Proxies
DEFA14A
Additional proxy soliciting materials
14 May 20
PX14A6G
Letter to shareholders
24 Apr 20
DEF 14A
Definitive proxy
20 Apr 20
DEFA14A
Additional proxy soliciting materials
22 Apr 19
PX14A6G
Letter to shareholders
1 Apr 19
DEF 14A
Definitive proxy
21 Mar 19
DEF 14A
Definitive proxy
13 Mar 18
DEF 14A
Definitive proxy
16 Apr 17
DEF 14A
Definitive proxy
17 Apr 16
DEF 14A
Definitive proxy
12 Apr 15
Other
UPLOAD
Letter from SEC
12 Apr 20
CORRESP
Correspondence with SEC
6 Apr 20
UPLOAD
Letter from SEC
24 Mar 20
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
22 May 18
CT ORDER
Confidential treatment order
25 Feb 18
Ownership
4
INCYTE / Dashyant Dhanak ownership change
5 Apr 21
4
INCYTE / JACQUALYN A FOUSE ownership change
1 Apr 21
4
INCYTE / EDMUND HARRIGAN ownership change
1 Apr 21
4
INCYTE / WENDY L DIXON ownership change
1 Apr 21
4
INCYTE / Paul J Clancy ownership change
1 Apr 21
4
INCYTE / JULIAN BAKER ownership change
1 Apr 21
4
INCYTE / Michael James Morrissey ownership change
31 Mar 21
4
INCYTE / Maria E Pasquale ownership change
16 Mar 21
4
INCYTE / Dashyant Dhanak ownership change
3 Mar 21
4
INCYTE / Herve Hoppenot ownership change
23 Feb 21
Patents
GRANT
Utility
Salts of an LSD1 inhibitor and processes for preparing the same
6 Apr 21
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
GRANT
Utility
Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
6 Apr 21
Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
APP
Utility
Treatment of B-cell Malignancies by a Combination Jak and PI3K Inhibitors
1 Apr 21
This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.
APP
Utility
Carboxamide Compounds and Uses Thereof
1 Apr 21
Inventors: Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Qinda Ye, Wenqing Yao
APP
Utility
Bicyclic Heterocycles As FGFR Inhibitors
1 Apr 21
Inventors: Oleg Vechorkin, Hai Fen Ye, Wenqing Yao
Transcripts
2020 Q4
Earnings call transcript
9 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
5 May 20
2019 Q4
Earnings call transcript
13 Feb 20
2019 Q3
Earnings call transcript
29 Oct 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
30 Apr 19
2018 Q4
Earnings call transcript
14 Feb 19
2018 Q3
Earnings call transcript
30 Oct 18
Reddit threads
50 tickers in the S&P 500 are at least 15% below their 52w highs. If you put equal capital in all of them, you'd probably be green
6 Apr 21
Vlad's testimony in a nutshell
19 Feb 21
stocks I like - for the hedge funds buying tech to track this
19 Feb 21
PLTR 440k YOLO - Holding since November and now loaded up on LEAPS 🚀
19 Feb 21
Palantir (PLTR) & What It Does
19 Feb 21
PLTR up 7% premarket. Also, the number of wsb comments on a stock relative to GME comments is apparently an analyst metric. 🍌
19 Feb 21
Daily Discussion Thread - February 9th, 2021
9 Feb 21
Daily Discussion Thread - February 8th, 2021
8 Feb 21
GME Aftermath
31 Jan 21
Daily Discussion Thread - November 5th, 2020
5 Nov 20